MedTrace Logo

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

NCT04562337 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2024-07-03

No results posted yet for this study

Summary

This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

SHR1316

Anti-PD-L1 antibody

DRUG

Carboplatin

Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

DRUG

Etoposide

Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

RADIATION

Radiation therapy

Thoracic radiation therapy ,TRT

DRUG

Cisplatin

Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Principal Investigators

  • JinMing Yu, PhD · Shandong Cancer Hospital and Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04562337 on ClinicalTrials.gov